Combinatorial therapy for prostate cancer bone metastasis:  A pharmaceutical mixture encompassing Metformin and Navitoclax (MAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 15/February/2019, 6.21 am